Findings from a recent poster study, presented at the 2019 Fall Society of Dermatology Physician Assistants Conference, study showed certolizumab pegol (Cimzia; CZP) effectively treated psoriasis on the head and neck.
In a post-hoc analysis, the researchers pooled data from CIMPASI-1 and CIMPASI-2. Participants in the trials were randomized 2:2:1 to CZP 400 mg every 2 weeks (n=175), CZP 200 mg every 2 weeks (n=186), or placebo (n=100). Main outcomes included the portion of participants who achieved 75% improvement and 90% improvement on the Psoriasis Area and Severity Index (PASI) at weeks 16 and 48.
A higher proportion of participants treated with CZP achieved 75% improvements in head and neck PASI scores at week 16 compared with placebo (CZP 400mg=78.8%; CZP 200mg=69.2%; placebo=16.2%), the researchers said. In addition, a higher proportion of participants treated with CZP achieved 90% improvement compared with placebo at week 16 (CZP 400mg= 69.7%; CZP 200mg=56.3%; placebo= 9.9%).
Improvements in head and neck psoriasis were seen for both dose of CZP, but the higher dose had the highest rates of responders, the researchers observed. These responses were maintained through week 48, they added.
At week 48, PASI 75% improvement was achieved in 76.6% of participants treated with 400mg CZP and 65.1% of participants treated with 200mg. Likewise, PASI 90% improvement was achieved by 67.9% and 55.6% of participants treated with CZP at week 48.
“CZP-treated patients demonstrated reductions in psoriasis of the head and neck region at week 16, which were maintained to week 48,” the researchers concluded. “These data suggest that CZP may be a suitable treatment option for patients with moderate to severe psoriasis affecting the head and neck.”
van d Kerkhof P, Pinter A, Boehnlein M, Kavanagh S, Crowley JJ. Efficacy of certolizumab pegol for psoriasis of the head and neck in two phase 3 clinical trials: CIMPASI-1 and CIMPASI-2. Presented at: 2019 Fall Society of Dermatology Physician Assistants Conference; November 20-24, 2019; Scottsdale, AZ.